{"id":"mcv-a-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains meningococcal serogroup A capsular polysaccharide conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. This triggers both humoral and cell-mediated immunity to prevent invasive meningococcal disease caused by serogroup A strains. The conjugate formulation improves immunological memory and provides longer-lasting protection compared to unconjugated polysaccharide vaccines.","oneSentence":"MCV-A vaccine stimulates the immune system to produce antibodies and cellular immunity against meningococcal serogroup A polysaccharide capsule.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:10.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup A"}]},"trialDetails":[{"nctId":"NCT03299426","phase":"PHASE3","title":"Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2018-02-21","conditions":"Typhoid","enrollment":30000},{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT06208683","phase":"PHASE4","title":"The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-11-04","conditions":"Mumps, Influenza","enrollment":400},{"nctId":"NCT05132855","phase":"PHASE1, PHASE2","title":"The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-11-30","conditions":"COVID-19, Breakthrough Infection","enrollment":340},{"nctId":"NCT04177485","phase":"NA","title":"Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-02-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1962},{"nctId":"NCT02165722","phase":"NA","title":"4 Pillars Toolkit for Adolescent Vaccination","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-09","conditions":"Adolescent HPV Vaccine, Adolescent Influenza Vaccine","enrollment":22},{"nctId":"NCT02003495","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2013-10","conditions":"Meningitis","enrollment":2195},{"nctId":"NCT02481232","phase":"PHASE1","title":"A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine","status":"UNKNOWN","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2015-06","conditions":"Meningococcal Meningitis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MCV-A vaccine","genericName":"MCV-A vaccine","companyName":"International Vaccine Institute","companyId":"international-vaccine-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"MCV-A is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroup A Neisseria meningitidis. Used for Prevention of meningococcal meningitis and septicemia caused by Neisseria meningitidis serogroup A.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}